Intel stock extends gains after report of possible U.S. government stake
Investing.com -- Indivior (LON:INDV) on Monday said it will delist from the London Stock Exchange (LON:LSEG) on July 25, ending its secondary listing and retaining Nasdaq as its sole primary market.
The company formally requested the Financial Conduct Authority and the LSE to cancel the listing and trading of its ordinary shares in London.
The last day of trading on the LSE will be July 24, with the delisting taking effect at 8 a.m. UK time the following day.
Jefferies analysts noted the board had previously maintained the London listing “for as long as it is considered to be in the best interests” of shareholders.
However, the decision follows a continued strategic shift toward the United States, where Indivior now derives more than 80% of its net revenue.
Indivior’s flagship product is Sublocade, a treatment for opioid addiction that is marketed in the U.S.
The company cited the geographic concentration of revenue, the predominance of its shareholder base in the U.S., and the liquidity profile of its shares as primary drivers for the exit.
As of May 27, about 75% of Indivior’s trading volume was on Nasdaq, and more than 70% of shares by value were held in the U.S.
Jefferies flagged the financial rationale behind the move, pointing to reduced costs associated with maintaining a dual listing and the benefit of aligning market announcements with U.S. trading hours.
The decision comes amid a broader restructuring under new leadership, with the company having appointed a new CEO earlier in the year.